Pharmaceutical Executive-01-01-2020

Pharm Exec’s annual forecast of the key issues facing biopharma leaders in the year ahead taps experts from several areas to uncover the seven new-decade trends to watch.

While drug pricing remains a top topic in the media at large and worthy of continuous exploration, we shift away in our latest pharma trends report, instead spotlighting seven key themes that we think are a bit less unpredictable in the months ahead.

Led in part by its new head of the Americas business, Sebastian Guth, Bayer went all in in 2019 on expanding pursuits in science and discovery, striking deals with 11 digital health startups and upping investment in disease-detection programs and patient engagement and education.

Challenges will mount to established models for researching, developing, and marketing new therapies.

The path for UK life sciences to factor prominently in transition-period maneuvering.

Three product launch trends driven by emerging biopharma.

What to make of new momentum in advancing health agenda.

Hari Pujar, chief technology officer of Spark Therapeutics, discusses the unique manufacturing and scale-up challenges involved with cell and gene therapy production.

Click the title above to open the Pharmaceutical Executive January 2020 issue in an interactive PDF format.

In China’s new reform-driven and fast-moving environment for healthcare innovation, intense market pressures and fierce competition will ultimately push all stakeholders to evolve their strategies-or face extinction.